Loading…

Autologous Stem Cell Mobilization in the Age of Plerixafor

Micro-Abstract Plerixafor is a potent stem cell–mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization or after prior failure of chemotherapy plus G-CSF wa...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2016-07, Vol.16 (7), p.411-416
Main Authors:	Cooper, Dennis L, Medoff, Erin, Patel, Natalie, Baker, Julie, Pratt, Kathryn, Foss, Francine, Seropian, Stuart E, Perreault, Sarah, Wu, Yanyun
Format:	Article
Language:	English
Subjects:	Adult Aged Antigens, CD34 - metabolism Female Graft Survival Granulocyte Colony-Stimulating Factor - pharmacology Growth factors Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Mobilization - methods Hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - metabolism Heterocyclic Compounds - pharmacology Humans Lymphoma - therapy Male Middle Aged Multiple myeloma Multiple Myeloma - therapy Plerixafor Stem cell mobilization Treatment Outcome Workflow
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c411t-32b76a7c24fb4e2a8ad21a1275c31380d9ec9be5d29d4d89ef2f8bdc40325eac3
cites	cdi_FETCH-LOGICAL-c411t-32b76a7c24fb4e2a8ad21a1275c31380d9ec9be5d29d4d89ef2f8bdc40325eac3
container_end_page	416
container_issue	7
container_start_page	411
container_title	Clinical lymphoma, myeloma and leukemia
container_volume	16
creator	Cooper, Dennis L Medoff, Erin Patel, Natalie Baker, Julie Pratt, Kathryn Foss, Francine Seropian, Stuart E Perreault, Sarah Wu, Yanyun
description	Micro-Abstract Plerixafor is a potent stem cell–mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization or after prior failure of chemotherapy plus G-CSF was associated with successful mobilization in 97.5% of patients, with target collections achieved in 60% of lymphoma and 72% of myeloma patients.
doi_str_mv	10.1016/j.clml.2016.04.007
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1800403528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2152265016300507</els_id><sourcerecordid>1800403528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-32b76a7c24fb4e2a8ad21a1275c31380d9ec9be5d29d4d89ef2f8bdc40325eac3</originalsourceid><addsrcrecordid>eNp9kU1P3DAQhq0KVCjtH-gB5djLhvHku0KVVisKSKBW2vZsOfZk8daJwU4Q8OvraIEDB06ew_O-Gj_D2FcOKQdenmxTZXubYpxTyFOA6gM7RF7gAsuy2XudCzhgn0LYRgCANx_ZAVaYFxnnh-z7chqddRs3hWQ9Up-syNrk2rXGmic5GjckZkjGG0qWG0pcl_y25M2D7Jz_zPY7aQN9eX6P2N-fZ39WF4urX-eXq-XVQuWcj4sM26qUlcK8a3NCWUuNXHKsCpXxrAbdkGpaKjQ2Otd1Qx12datVDhkWJFV2xL7tem-9u5sojKI3QcU15UBxbcFrgAgXWEcUd6jyLgRPnbj1ppf-UXAQszOxFbMzMTsTkIuoJIaOn_untif9GnmRFIHTHUDxl_eGvAjK0KBIG09qFNqZ9_t_vIkrawajpP1HjxS2bvJD9Ce4CChArOerzUfjZQZQxIL_tuKRFw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1800403528</pqid></control><display><type>article</type><title>Autologous Stem Cell Mobilization in the Age of Plerixafor</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Cooper, Dennis L ; Medoff, Erin ; Patel, Natalie ; Baker, Julie ; Pratt, Kathryn ; Foss, Francine ; Seropian, Stuart E ; Perreault, Sarah ; Wu, Yanyun</creator><creatorcontrib>Cooper, Dennis L ; Medoff, Erin ; Patel, Natalie ; Baker, Julie ; Pratt, Kathryn ; Foss, Francine ; Seropian, Stuart E ; Perreault, Sarah ; Wu, Yanyun</creatorcontrib><description>Micro-Abstract Plerixafor is a potent stem cell–mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization or after prior failure of chemotherapy plus G-CSF was associated with successful mobilization in 97.5% of patients, with target collections achieved in 60% of lymphoma and 72% of myeloma patients.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2016.04.007</identifier><identifier>PMID: 27245311</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Antigens, CD34 - metabolism ; Female ; Graft Survival ; Granulocyte Colony-Stimulating Factor - pharmacology ; Growth factors ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Mobilization - methods ; Hematopoietic stem cell transplantation ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic Stem Cells - drug effects ; Hematopoietic Stem Cells - metabolism ; Heterocyclic Compounds - pharmacology ; Humans ; Lymphoma - therapy ; Male ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - therapy ; Plerixafor ; Stem cell mobilization ; Treatment Outcome ; Workflow</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2016-07, Vol.16 (7), p.411-416</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-32b76a7c24fb4e2a8ad21a1275c31380d9ec9be5d29d4d89ef2f8bdc40325eac3</citedby><cites>FETCH-LOGICAL-c411t-32b76a7c24fb4e2a8ad21a1275c31380d9ec9be5d29d4d89ef2f8bdc40325eac3</cites><orcidid>0000-0002-9708-5252</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27245311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cooper, Dennis L</creatorcontrib><creatorcontrib>Medoff, Erin</creatorcontrib><creatorcontrib>Patel, Natalie</creatorcontrib><creatorcontrib>Baker, Julie</creatorcontrib><creatorcontrib>Pratt, Kathryn</creatorcontrib><creatorcontrib>Foss, Francine</creatorcontrib><creatorcontrib>Seropian, Stuart E</creatorcontrib><creatorcontrib>Perreault, Sarah</creatorcontrib><creatorcontrib>Wu, Yanyun</creatorcontrib><title>Autologous Stem Cell Mobilization in the Age of Plerixafor</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>Micro-Abstract Plerixafor is a potent stem cell–mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization or after prior failure of chemotherapy plus G-CSF was associated with successful mobilization in 97.5% of patients, with target collections achieved in 60% of lymphoma and 72% of myeloma patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, CD34 - metabolism</subject><subject>Female</subject><subject>Graft Survival</subject><subject>Granulocyte Colony-Stimulating Factor - pharmacology</subject><subject>Growth factors</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Mobilization - methods</subject><subject>Hematopoietic stem cell transplantation</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Hematopoietic Stem Cells - metabolism</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>Humans</subject><subject>Lymphoma - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - therapy</subject><subject>Plerixafor</subject><subject>Stem cell mobilization</subject><subject>Treatment Outcome</subject><subject>Workflow</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kU1P3DAQhq0KVCjtH-gB5djLhvHku0KVVisKSKBW2vZsOfZk8daJwU4Q8OvraIEDB06ew_O-Gj_D2FcOKQdenmxTZXubYpxTyFOA6gM7RF7gAsuy2XudCzhgn0LYRgCANx_ZAVaYFxnnh-z7chqddRs3hWQ9Up-syNrk2rXGmic5GjckZkjGG0qWG0pcl_y25M2D7Jz_zPY7aQN9eX6P2N-fZ39WF4urX-eXq-XVQuWcj4sM26qUlcK8a3NCWUuNXHKsCpXxrAbdkGpaKjQ2Otd1Qx12datVDhkWJFV2xL7tem-9u5sojKI3QcU15UBxbcFrgAgXWEcUd6jyLgRPnbj1ppf-UXAQszOxFbMzMTsTkIuoJIaOn_untif9GnmRFIHTHUDxl_eGvAjK0KBIG09qFNqZ9_t_vIkrawajpP1HjxS2bvJD9Ce4CChArOerzUfjZQZQxIL_tuKRFw</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Cooper, Dennis L</creator><creator>Medoff, Erin</creator><creator>Patel, Natalie</creator><creator>Baker, Julie</creator><creator>Pratt, Kathryn</creator><creator>Foss, Francine</creator><creator>Seropian, Stuart E</creator><creator>Perreault, Sarah</creator><creator>Wu, Yanyun</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9708-5252</orcidid></search><sort><creationdate>20160701</creationdate><title>Autologous Stem Cell Mobilization in the Age of Plerixafor</title><author>Cooper, Dennis L ; Medoff, Erin ; Patel, Natalie ; Baker, Julie ; Pratt, Kathryn ; Foss, Francine ; Seropian, Stuart E ; Perreault, Sarah ; Wu, Yanyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-32b76a7c24fb4e2a8ad21a1275c31380d9ec9be5d29d4d89ef2f8bdc40325eac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, CD34 - metabolism</topic><topic>Female</topic><topic>Graft Survival</topic><topic>Granulocyte Colony-Stimulating Factor - pharmacology</topic><topic>Growth factors</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Mobilization - methods</topic><topic>Hematopoietic stem cell transplantation</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Hematopoietic Stem Cells - metabolism</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>Humans</topic><topic>Lymphoma - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - therapy</topic><topic>Plerixafor</topic><topic>Stem cell mobilization</topic><topic>Treatment Outcome</topic><topic>Workflow</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cooper, Dennis L</creatorcontrib><creatorcontrib>Medoff, Erin</creatorcontrib><creatorcontrib>Patel, Natalie</creatorcontrib><creatorcontrib>Baker, Julie</creatorcontrib><creatorcontrib>Pratt, Kathryn</creatorcontrib><creatorcontrib>Foss, Francine</creatorcontrib><creatorcontrib>Seropian, Stuart E</creatorcontrib><creatorcontrib>Perreault, Sarah</creatorcontrib><creatorcontrib>Wu, Yanyun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cooper, Dennis L</au><au>Medoff, Erin</au><au>Patel, Natalie</au><au>Baker, Julie</au><au>Pratt, Kathryn</au><au>Foss, Francine</au><au>Seropian, Stuart E</au><au>Perreault, Sarah</au><au>Wu, Yanyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autologous Stem Cell Mobilization in the Age of Plerixafor</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>16</volume><issue>7</issue><spage>411</spage><epage>416</epage><pages>411-416</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>Micro-Abstract Plerixafor is a potent stem cell–mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal granulocyte-colony stimulating factor (G-CSF) mobilization or after prior failure of chemotherapy plus G-CSF was associated with successful mobilization in 97.5% of patients, with target collections achieved in 60% of lymphoma and 72% of myeloma patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27245311</pmid><doi>10.1016/j.clml.2016.04.007</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9708-5252</orcidid></addata></record>
fulltext	fulltext
identifier	ISSN: 2152-2650
ispartof	Clinical lymphoma, myeloma and leukemia, 2016-07, Vol.16 (7), p.411-416
issn	2152-2650 2152-2669
language	eng
recordid	cdi_proquest_miscellaneous_1800403528
source	ScienceDirect Freedom Collection 2022-2024
subjects	Adult Aged Antigens, CD34 - metabolism Female Graft Survival Granulocyte Colony-Stimulating Factor - pharmacology Growth factors Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Mobilization - methods Hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - metabolism Heterocyclic Compounds - pharmacology Humans Lymphoma - therapy Male Middle Aged Multiple myeloma Multiple Myeloma - therapy Plerixafor Stem cell mobilization Treatment Outcome Workflow
title	Autologous Stem Cell Mobilization in the Age of Plerixafor
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T22%3A16%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autologous%20Stem%20Cell%20Mobilization%20in%20the%20Age%20of%20Plerixafor&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Cooper,%20Dennis%20L&rft.date=2016-07-01&rft.volume=16&rft.issue=7&rft.spage=411&rft.epage=416&rft.pages=411-416&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2016.04.007&rft_dat=%3Cproquest_cross%3E1800403528%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-32b76a7c24fb4e2a8ad21a1275c31380d9ec9be5d29d4d89ef2f8bdc40325eac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1800403528&rft_id=info:pmid/27245311&rfr_iscdi=true